Long-acting reversible contraceptive (LARCs) methods.


Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 02 10 2019
revised: 04 12 2019
accepted: 10 12 2019
pubmed: 6 2 2020
medline: 28 7 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

Unplanned pregnancy (UP) is a public health problem, which affects millions of women worldwide. Providing long-acting reversible contraceptive (LARC) methods is an excellent strategy to avoid or at least reduce UP, because the effectiveness of these methods is higher than other methods, and is indeed comparable to that of permanent contraception. As the initial introduction of the inert plastic intrauterine device (IUD) and of the six-rod implant, pharmaceutical companies have introduced a copper IUD (Cu-IUD), different models of levonorgestrel-releasing intrauterine system (LNG IUS), and one and two-rod implants, which certainly improved women's LARC options. The main characteristic of LARCs is that they provide high contraceptive effectiveness with a single intervention, and that they can be used for a long time. Emerging evidence from the last few years has demonstrated that it is possible to extend the use of the 52 mg LNG IUS and of the etonogestrel-implant beyond five- and three years, respectively, which adds new value to these LARCs.

Identifiants

pubmed: 32014434
pii: S1521-6934(19)30178-6
doi: 10.1016/j.bpobgyn.2019.12.002
pii:
doi:

Substances chimiques

Contraceptive Agents 0
Contraceptive Agents, Female 0
Drug Implants 0
Levonorgestrel 5W7SIA7YZW

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

28-40

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest LB and IM have received honoraria as members of advisory boards and have been invited as speakers at scientific meetings for Bayer Healthcare Pharmaceuticals and Merck. None of the other authors have any conflicts of interest to declare.

Auteurs

Luis Bahamondes (L)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences (UNICAMP), Campinas, SP, Brazil. Electronic address: bahamond@caism.unicamp.br.

Arlete Fernandes (A)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences (UNICAMP), Campinas, SP, Brazil.

Ilza Monteiro (I)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences (UNICAMP), Campinas, SP, Brazil.

M Valeria Bahamondes (MV)

Centro Latinoamericano de Perinatologia, Salud de la Mujer y Reproductiva, Montevideo, Uruguay.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH